Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03874052
Title Ruxolitinib in Combination With Venetoclax for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

acute myeloid leukemia

Therapies

Ruxolitinib + Venetoclax

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
OHSU Knight Cancer Institute Portland Oregon 97239 United States Details
UT Southwestern/Simmons Cancer Center-Dallas Dallas Texas 75390 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field